|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dutkowski P, Linecker M, DeOliveira ML,
Mullhaupt B and Clavien PA: Challenges to liver transplantation and
strategies to improve outcomes. Gastroenterology. 148:307–323.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramesh H: Resection for hepatocellular
carcinoma. J Clin Exp Hepatol. 4 Suppl 3:S90–S96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arzumanyan A, Reis HM and Feitelson MA:
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ivkovic Catela T, Voss G, Cornella H and
Ceder Y: microRNAs as cancer therapeutics: A step closer to
clinical application. Cancer Lett. 407:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayes J, Peruzzi PP and Lawler S:
microRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mazzaferro V, Regalia E, Doci R, Andreola
S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and
Gennari L: Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med.
334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L,
Yan S, Wu L, Geng L, Ke Q, et al: Liver transplantation for
hepatocellular carcinoma beyond the Milan criteria. Gut.
65:1035–1041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng SS, Xu X, Wu J, Chen J, Wang WL,
Zhang M, Liang TB and Wu LM: Liver transplantation for
hepatocellular carcinoma: Hangzhou experiences. Transplantation.
85:1726–1732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Z, Zhou L, Wu LM, Lai MC, Xie HY,
Zhang F and Zheng SS: Overexpression of long non-coding RNA HOTAIR
predicts tumor recurrence in hepatocellular carcinoma patients
following liver transplantation. Ann Surg Oncol. 18:1243–1250.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang H, Zheng W, Shuai X, Chang RM, Yu L,
Fang F and Yang LY: microRNA-424 inhibits Akt3/E2F3 axis and tumor
growth in hepatocellular carcinoma. Oncotarget. 6:27736–27750.
2015.PubMed/NCBI
|
|
16
|
Zhang Y, Li T, Guo P, Kang J, Wei Q, Jia
X, Zhao W, Huai W, Qiu Y, Sun L and Han L: miR-424-5p reversed
epithelial-mesenchymal transition of anchorage-independent HCC
cells by directly targeting ICAT and suppressed HCC progression.
Sci Rep. 4:62482014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang F, Wu LM, Zhou L, Chen QX, Xie HY,
Feng XW and Zheng SS: Predictive value of expression and promoter
hypermethylation of XAF1 in hepatitis B virus-associated
hepatocellular carcinoma treated with transplantation. Ann Surg
Oncol. 15:3494–3502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin
SY, Liu XC, Zhou L, Xu XB, Sun YL and Zheng SS: MMP2 promoter
polymorphism (C-1306T) and risk of recurrence in patients with
hepatocellular carcinoma after transplantation. Clin Genet.
73:273–278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY,
Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1
overexpression predicts tumor recurrence of hepatocellular
carcinoma after liver transplantation. Med Oncol. 29:1810–1816.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaiser J: The cancer stem cell gamble.
Science. 347:226–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt
JR, Cameron AM, Hong J and Busuttil RW: Recurrence of
hepatocellular carcinoma following liver transplantation: A review
of preoperative and postoperative prognostic indicators. Arch Surg.
143:182–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schutte K, Schulz C, Link A and
Malfertheiner P: Current biomarkers for hepatocellular carcinoma:
Surveillance, diagnosis and prediction of prognosis. World J
Hepatol. 7:139–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE,
Park YY, Jeong W, Lee SS, Park ES and Kaseb A: Genomic predictors
for recurrence patterns of hepatocellular carcinoma: Model
derivation and validation. PLoS Med. 11:e10017702014. View Article : Google Scholar : PubMed/NCBI
|
